Yposkesi, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies, announced the launch of project SKY, the construction of Yposkesi’s second commercial cell and gene therapy facility and a new global resource for drug developers of biologics, also called ATMPs (Advanced Therapy Medicinal Products). ATMPs treat patients living with rare and life-threatening diseases.
In March 2021, Yposkesi welcomed SK Pharmteco, a global CDMO player, as a new majority equity shareholder in its company. Backed by SK Pharmteco, Yposkesi is investing €58M (approx. $71M) in the new 5,000m2 (50,000 ft²) site, making it one of the largest ATMP facilities in Europe. Project SKY will create approximately 80 new jobs by 2023. With this new state-of-the-art facility, designed for European and American GMP compliance, Yposkesi will double its production surface to 10,000m2 (100,000 ft²).
The new building will house two additional production lines with several 1000L scale bioreactors. This allows Yposkesi to enhance its competitive offering through its ability to support client projects from the early process development phases up to large scale manufacturing of approved drugs.
Construction began on May 25, 2021 on a site adjacent to Yposkesi’s current 5,000m2 commercial facility. By 2023, equipment consisting of several 1000L bioreactors, chromotography and purification skids will be installed. The new facility will also incorporate a centralized warehouse, capacity for media, solutions and mountings preparation, drug substance production suites and storage, and quality control lab resources.
Yposkesi’s plant extension, designed as an ultramodern cGMP facility, is scheduled to be qualified and operational in conformance with EMA and FDA regulations in 2023.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!